Blonder Tongue Laboratories, Inc. (BDRLQ) Stock Price & Analysis
Blonder Tongue Laboratories, Inc. (BDRLQ) — price $0.0002 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Blonder Tongue Laboratories, Inc. · BDRLQ
Blonder Tongue Laboratories, Inc. (BDRLQ) is a technology company specializing in television signal processing and broadband networks, offering a range of products including encoders, transcoders, and customer premises equipment.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0002 |
| Change on the day | 0.00% |
| Shares traded on the day | 26.2K |
Price & events
Other perspectives
Council score for Blonder Tongue Laboratories (BDRLQ): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Blonder Tongue Laboratories (BDRLQ), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Blonder Tongue Laboratories, Inc. (BDRLQ) is the company analyzed here. It employs 67 people. In Q1 FY2025 it reported revenue of $3M and net income of -$314,000.
What do the latest results show for Blonder Tongue Laboratories (BDRLQ)?
Short answer · as of
The most recent reported quarter, Q1 FY2025, carried revenue of $3M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2025 | $3M | -$314,000 | -$0.02 (diluted) |
| Q4 FY2024 | $3M | -$483,000 | -$0.03 (diluted) |
| Q3 FY2024 | $3M | -$427,000 | -$0.03 (diluted) |
| Q2 FY2024 | $3M | -$98,000 | -$0.01 (diluted) |
What are the financial strengths and risks for Blonder Tongue Laboratories (BDRLQ)?
Short answer · as of
The distress and quality screens read Altman Z -4.42 · Piotroski F 4. Trailing ratios: ROE 110.8% · ROA -13.2% · current ratio 0.60.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 3
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BDRLQ in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BDRLQ in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Blonder Tongue Laboratories Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the BDRLQ research dossier (written Jun 14, 2026 by gpt-4o-mini). Figures in this section are not part of the source register.
What are the main risks for BDRLQ?
Blonder Tongue Laboratories, Inc. faces several risks, including regulatory scrutiny due to its OTC market operations, which may lead to increased compliance costs.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 11 figures on this page — 9 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com